Salvagno Gian L, Lippi Giuseppe, Montagnana Martina, Poli Giovanni, Giavarina Davide, Manzato Franco, Guidi Gian C
Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università di Verona, Verona, Italy.
Blood Coagul Fibrinolysis. 2008 Dec;19(8):817-21. doi: 10.1097/MBC.0b013e32830f1bae.
We evaluated the analytical performance of the new commercial HemosIL D-Dimer HS, a latex-enhanced turbidimetric immunoassay, from Instrumentation Laboratory for D-dimer measurement on the ACL TOP automated analyzer. The recommended cut-off for this immunoassay is 243 ng/ml. The within-run and between-run coefficients of variations of D-Dimer HS for low, intermediate and high D-dimer concentrations were: 3.3-6.6%, 2.3-2.6%, 2.4-3.2%, respectively. The assay was proven linear in a range of D-dimer concentrations comprised between 319 and 2274 ng/ml. Results of 171 citrated plasma samples were compared with those of the reference commercial immunoassay VIDAS D-Dimer. Although the nonparametric regression according to the method of Passing and Bablok and the relative Spearman's correlation coefficient were excellent (HemosIL D-Dimer HS = 1.30 x VIDAS - 384; r = 0.964, P < 0.001), some discrepancies could be observed in Bland-Altman plots analysis. On the basis of the present evaluation, we conclude that the analytical performance and the main technical features of new HemosIL D-Dimer HS assay make it a suitable method for the rapid quantification of D-dimer in clinical laboratories. Further studies are however needed to confirm the safety of the assay and to determine the most optimal cutoff level in patients with venous thromboembolism.
我们评估了新的商业化HemosIL D - 二聚体HS(一种乳胶增强比浊免疫测定法)在ACL TOP自动分析仪上进行D - 二聚体测量时的分析性能。该免疫测定法的推荐临界值为243 ng/ml。低、中、高D - 二聚体浓度下D - 二聚体HS的批内和批间变异系数分别为:3.3 - 6.6%、2.3 - 2.6%、2.4 - 3.2%。该测定法在319至2274 ng/ml的D - 二聚体浓度范围内被证明呈线性。将171份枸橼酸盐血浆样本的结果与参考商业化免疫测定法VIDAS D - 二聚体的结果进行了比较。尽管根据Passing和Bablok方法的非参数回归以及相对Spearman相关系数都很出色(HemosIL D - 二聚体HS = 1.30×VIDAS - 384;r = 0.964,P < 0.001),但在Bland - Altman图分析中仍可观察到一些差异。基于目前的评估,我们得出结论,新的HemosIL D - 二聚体HS测定法的分析性能和主要技术特征使其成为临床实验室快速定量D - 二聚体的合适方法。然而,还需要进一步研究来确认该测定法的安全性,并确定静脉血栓栓塞患者的最佳临界水平。